Abdominopelvic post-irradiation morphea in a prostate cancer patient: the first case of an under recognized condition by Di Meo, N. et al.
Abdominopelvic post-irradiation morphea in a prostate cancer patient: 
the first case of an under-recognized condition
Nicola di Meo1, Cecilia Noal1 ✉, Sara Trevisini1, Bruno Ulessi1, Giusto Trevisan1
1Dermatology Department, University of Trieste, Trieste, Italy. ✉ Corresponding author: cecilia.noal@gmail.com
67
2015;24:67-68 
doi: 10.15570/actaapa.2015.17
To the Editor:
Post-irradiation morphea (PIM) is a rare but well-documented 
under-recognized complication of radiotherapy (1, 2). To our 
knowledge, cases of PIM after radiotheraphy for prostatic carci-
noma have never been reported in the literature. A 74-year-old 
overweight Caucasian male referred to our clinic for sclerotic cu-
taneous involvement of the abdominopelvic region. He reported 
a history of radical surgery for prostatic carcinoma (pT2a N0 M0) 
followed by adjuvant radiotherapy (70Gy in 35 fractions) in 2010. 
One month earlier, an erythematous plaque had developed on 
the pelvic region and it gradually extended, becoming indurate, 
thick, and painful. He reported progressive cutaneous incarcera-
tion, with motility distress. Upon clinical examination, he pre-
sented with an indurate yellowish-white sclerotic plaque involving 
the upper thighs, pelvic region, and lower abdomen (Figs. 1a, b).
Laboratory investigations were negative for autoantibody pro-
file, hepatitis, and Borrelia burgdorferi. Histological examination 
revealed a lymphocytic infiltration of the reticular dermis with 
plasma cells (Fig. 2). Clinical and instrumental exams did not re-
veal any relapse of cancer or metastatic disease. Because of his 
anamnesis, clinical findings, and histological features, a diag-
nosis of PIM was made. The patient started therapy with UVA1 
phototherapy associated with daily topical calcipotriol. Clinical 
improvement was achieved after 3 months, with a mild softening 
of the skin involved.
Post-irradiation morphea (PIM) is a rare skin complication of 
radiotherapy. In a previous study, the incidence of localized mor-
phea following radiotherapy appears to be approximately two out 
of every 1,000 patients (3). It can occur 1 to 12 months after radia-
tion, and as much as 32 years later. PIM is more frequent in female 
patients; there has been only one case in a male with subcutane-
ous lymphoma (4). The majority of PIM occurs in patients treat-
ed for breast carcinoma. It is a less common complication after 
neoadjuvant radiotherapy for head and neck cancer, endometrial 
cancer, and gastrointestinal neoplasia (5). PIM is characterized by 
sclerotic plaque, erythema, and induration. Usually it is restricted 
within the radiation area, but in the literature PIM is reported to 
extend beyond the irradiated area or involve a distant site (6–7). 
PIM often presents a difficult diagnosis, especially in non-clas-
sical presentations. Radiation-induced fibrosis (RIF), radiation 
recall dermatitis, post-irradiation sclerodermatous panniculitis, 
and cancerous sclerosing recurrence are the main differential 
diagnoses. Skin biopsy results are helpful for distinguishing the 
disease. PIM occurs later in relation to radiotherapy compared to 
RIF, which usually appears in the first 3 months. There is usually
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Figure 1A and 1B | An indurate yellowish-white sclerotic plaque involving the 
upper thighs, pelvic region, and lower abdomen.
Figure 2 | Lymphocytic infiltration of reticular dermis with plasma cells.
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an abrupt onset in PIM, with an initial erythema and thickening 
that is not observed in RIF (4). Histological findings demonstrat-
ed dermal inflammatory infiltrates, which are absent in RIF. Ra-
diation recall dermatitis has been defined as the skin “recalling” 
previous radiation exposure in response to the administration of 
drugs (8). The post-irradiation sclerodermatous panniculitis histo-
logical pattern reveals significant changes in the subcutaneous tis-
sues with lobular panniculitis. The dermis is nearly unaffected (9).
Treatment of post-irradiation morphea is difficult, and many 
cases are recalcitrant to therapy. Topical and intralesional corti-
costeroids, oral and systemic antibiotics, topical hyaluronidase 
and methotrexate, and chloroquine are used in PIM (10). In some 
patients, a spontaneous gradual softening of the skin could be ob-
served. In the literature, several studies reported the effectiveness 
of a combined treatment of calcipotriol and UVA1 irradiation to 
treat morphea (11). The pathogenesis is still unknown. Davis et al. 
proposed that radiotherapy induces neoantigen formation, which 
starts a T-cell response months to years after exposure, stimulat-
ing the production of transforming growth factor (TGF-b). TGF-b 
induces fibroblast activation and the production of extracellular 
matrix proteins, and inhibits the degradation of matrix proteins, 
implying extensive fibrosis (12). Hermann et al. suggest that there 
is a higher secretion of Th2cytokines (interleukin 4, interleukin 5), 
which stimulate collagen synthesis (13). Another theory explains 
the development of PIM due to a premature terminal differentia-
tion of fibroblast to myofibroblast (14). There seem to be no clear 
predictive factors predicting the development of RIM. Radiothera-
py total dose, age of the patient, dose per fraction, acute skin side 
effects, or history of autoimmune diseases appear not to be impor-
tant risk factors (10). Breast size seems to play a role in the devel-
opment of PIM, perhaps because large breasts have a higher fat 
content or the radiotherapy dose is inhomogeneous (15). Similar 
anatomical conditions can be detected in an overweight patient, 
as in our case. PIM is a rare complication with important adverse 
side effects of radiotherapy. In the literature, PIM has mainly been 
described in females treated for breast cancer and it extends with-
in the irradiated area. Considering the amount of radiotherapy for 
prostate cancer since its introduction, it is possible that our case 
is the first case of an under-recognized condition.
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